Gedeon Richter PLC (RGEDF) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Gedeon Richter PLC stock $84.74, price $40.96, upside +106.9%, quality 74 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range $10.78 – $43.76 · fair‑value band $63.55 – $105.92 · the $40.96 price screens below the $84.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Gedeon Richter in your weekly email
Every Wednesday you see whether Gedeon Richter is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives.
It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases.
In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic.
Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment.
It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management.
Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Stock analysis
Gedeon Richter PLC (RGEDF) currently trades at $40.96, while our model-based Fair Value estimate is $84.74, implying the stock looks roughly 51.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $102.26 per share, and 20 of the 26 models we run sit above the $40.96 price.
Bear case: the Dividend Discount group reads lowest at $26.43, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $63.55 (bear) to $105.92 (bull), the price of $40.96 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Gedeon Richter PLC reported revenue of 923B HUF in FY2025 versus 631B HUF in FY2021, a compound +10.0%/yr. Reported net income was 231B HUF in FY2025, compounding +13.4%/yr from FY2021.
Key figures
Market cap $7.5B Mid · P/E ratio 11.4 · P/S ratio 2.85 · EPS (TTM) $3.60 · Net margin 25.0% · Return on equity 16.2% · Return on assets (EBIT) 15.0% · Revenue (TTM) 811B HUF.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at 107%, RGEDF screens cheaper than that median.
Fair Value models
Bear$63.55Fair Value $84.74Bull$105.92
Price $40.96 · Upside +106.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.99 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +9.7% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in HUF ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in HUF: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.5% vs 15.8%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 35%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in HUF, Hungary: IMF forecast 3.3% a year to 2030, 5.6% from 2016 to 2025) that is about −10.7% a year for the price and +2.3% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 577 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+106.9% · Top 25%
Profitability
Return on equity (12 months)16.2% · Top 25%
Return on assets13.8% · Top 25%
Net margin (12 months)23.3% · Top 25%
Operating margin (12 months)0.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)0.0% · Below median
Dividend yield (12 months)5.3% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Gedeon Richter PLC (RGEDF) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of $84.74 versus a price of $40.96, about +107% upside (undervalued).
What is the fair value of RGEDF?
Our model-based fair value for Gedeon Richter PLC is $84.74 (as of Oct 27, 2026), built from audited fundamentals. The current price: $40.96.
What is the quality score of RGEDF?
Gedeon Richter PLC has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gedeon Richter PLC (RGEDF)?
Our model-based price target is the fair value of $84.74 (as of Oct 27, 2026) from 26 valuation models. Cautious scenario $63.55, optimistic scenario $105.92. It is a calculation from audited fundamentals, not an analyst target.
What is the Gedeon Richter PLC stock forecast for 2026?
Our models put fair value at $84.74, about +107% upside versus a price of $40.96 (undervalued). Cautious scenario $63.55, optimistic scenario $105.92. The calculation is refreshed regularly with new filings.
What is the revenue of Gedeon Richter PLC (RGEDF)?
Gedeon Richter PLC reported trailing-twelve-month revenue of about 811B HUF (latest available figure, as of Oct 27, 2026).
What growth is priced into Gedeon Richter PLC (RGEDF)?
For today's price to be fair in a discounted-cash-flow model, Gedeon Richter PLC would have to grow free cash flow by -7.8 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.3 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of RGEDF use?
Our models discount Gedeon Richter PLC at 8.5 %: a base by market capitalisation (mid), damped by beta 0.35, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Gedeon Richter PLC that is -7.8 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Gedeon Richter PLC (RGEDF) delivered so far?
Over the past 5 years revenue at Gedeon Richter PLC grew +10.3 % a year. The price currently implies -7.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Gedeon Richter PLC (RGEDF) growing?
The median revenue growth in the sector is +6.0 % a year. That is the yardstick for the growth priced into Gedeon Richter PLC (-7.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Gedeon Richter PLC (RGEDF)?
The free-cash-flow yield on the price is 10.09 %: that much free cash flow Gedeon Richter PLC produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Gedeon Richter PLC (RGEDF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gedeon Richter PLC it is $84.74 per share (as of Oct 27, 2026), against a price of $40.96. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Gedeon Richter PLC stock overvalued or undervalued in 2026?
As of Oct 27, 2026, RGEDF trades below its calculated fair value: price $40.96, fair value $84.74, a gap of about +107% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RGEDF?
No. The price is what the market pays today ($40.96); the fair value is what the company's own numbers justify ($84.74). For Gedeon Richter PLC the two are $43.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gedeon Richter PLC worth?
The market values Gedeon Richter PLC at about $7.5B (market capitalisation, as of Oct 27, 2026). Per share that is $40.96; our models calculate a fair value of $84.74 per share.
What do the bullish and bearish scenarios say about RGEDF?
Our models span a range for Gedeon Richter PLC: cautious scenario $63.55, base $84.74, optimistic $105.92 per share (as of Oct 27, 2026, price $40.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RGEDF?
Gedeon Richter PLC trades at a price-to-earnings ratio of 11.4 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $84.74 is built from several models across several years. Other multiples: P/B 1.8, P/S 3.0, EV/EBITDA 6.3.
How solid is the balance sheet of Gedeon Richter PLC (RGEDF)?
Balance-sheet figures for Gedeon Richter PLC (as of Oct 27, 2026): return on equity 16.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is RGEDF from its 52-week high?
Gedeon Richter PLC trades at $40.96, about 6% below its 52-week high of $43.76 and 48% above the low of $27.61 (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of $84.74 is for.
Which stocks are comparable to Gedeon Richter PLC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gedeon Richter PLC stock attractive at the current price?
The data as of Oct 27, 2026: price $40.96, calculated fair value $84.74 (+107%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RGEDF calculated?
We run Gedeon Richter PLC through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $84.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Gedeon Richter PLC currently trades 52 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gedeon Richter PLC (RGEDF)?
The closing price on Oct 29, 2026 was $40.96. Our model-based fair value is $84.74, about +107% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gedeon Richter PLC right now?
The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($63.55). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Gedeon Richter PLC (RGEDF) come from?
Earnings per share at Gedeon Richter PLC grew +17.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.0 %, EBIT margin +9.0 %, tax rate −1.1 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Gedeon Richter PLC
How large is the market capitalisation of Gedeon Richter PLC (RGEDF)?
The market capitalisation of Gedeon Richter PLC is $7.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gedeon Richter PLC (RGEDF)?
The price-to-sales ratio of Gedeon Richter PLC is 2.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gedeon Richter PLC (RGEDF)?
Earnings per share at Gedeon Richter PLC are $3.60 (price ÷ EPS = P/E 11.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gedeon Richter PLC (RGEDF)?
The net margin of Gedeon Richter PLC is 25.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gedeon Richter PLC (RGEDF)?
The return on equity (ROE) of Gedeon Richter PLC is 16.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gedeon Richter PLC (RGEDF)?
On an EBIT basis the return on assets of Gedeon Richter PLC is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast are earnings growing at Gedeon Richter PLC (RGEDF)?
Earnings per share at Gedeon Richter PLC are growing −26.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Gedeon Richter PLC (RGEDF) hold?
Gedeon Richter PLC holds more cash than debt, 175B HUF net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Gedeon Richter PLC in the live analysis
One click puts Gedeon Richter PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026